Novartis joins Cancer Research UK on rare cancers study by FMR Global | Dec 15, 2022 | FMR GLOBAL | 0 comments DETERMINE trial aims to discover if current treatments could benefit patients with other cancer types Submit a Comment Cancel replyYour email address will not be published. Required fields are marked *Comment * Name * Email * Website Save my name, email, and website in this browser for the next time I comment.
